Literature DB >> 10489101

The effect of erythropoietin on interleukin-1beta mediated increase in nitric oxide synthesis in vascular smooth muscle cells.

T Akimoto1, E Kusano, S Muto, N Fujita, K Okada, T Saito, N Komatsu, S Ono, S Ebata, Y Ando, S Homma, Y Asano.   

Abstract

OBJECTIVE: Recently, we observed that recombinant human erythropoietin (rHuEPO) inhibits the interleukin (IL)-1beta induced nitric oxide (NO) production and inducible NO synthase (iNOS) expression in cultured rat vascular smooth muscle cells (VSMC). The mechanisms of these inhibitory effects of rHuEPO were evaluated.
METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was performed to identify a specific erythropoietin receptor (EpoR). Tyrosine phosphorylation of phospholipase C (PLC) was analyzed by combination of immunoprecipitation and Western blotting. Protein kinase C (PKC) activities were analyzed by phosphorylation assay of myelin basic protein (MBP4-14). VSMC were incubated with test agents for 24 h and nitrite as a stable NO metabolite was measured. iNOS mRNA and protein expression was analyzed by Northern and Western blotting, respectively.
RESULTS: RT-PCR analysis revealed that EpoR m-RNA was expressed; furthermore, it might be alternatively spliced in VSMC. rHuEPO induced tyrosine phosphorylation of PLC-gamma1 and activation of PKC. rHuEPO inhibited not only IL-1beta induced nitrite production, but also the expression of iNOS mRNA and protein. These inhibitory effects of rHuEPO were reversed in the presence of PKC inhibitors, calphostin C (1 pmol/l) or staurosporine (10 nmol/l). PKC activation by phorbol myristate acetate inhibited nitrite production. The inhibitory effect of rHuEPO on IL-1beta induced nitrite production was also eliminated in PKC depleted cells or in the existence of anti-EpoR antibody.
CONCLUSION: rHuEPO inhibits IL-1beta induced NO production by suppressing iNOS mRNA and protein expressions through EpoR, and the PLC-gamma1 and PKC pathway may be involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489101     DOI: 10.1097/00004872-199917090-00003

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Cardiovascular effects of erythropoietin an update.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  Adv Pharmacol       Date:  2010

Review 2.  Erythropoetin as a novel agent with pleiotropic effects against acute lung injury.

Authors:  Sotirios Kakavas; Theano Demestiha; Panagiotis Vasileiou; Theodoros Xanthos
Journal:  Eur J Clin Pharmacol       Date:  2010-11-11       Impact factor: 2.953

3.  A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats.

Authors:  Jacob Bertram Springborg; XiaoDong Ma; Per Rochat; Gitte Moos Knudsen; Ole Amtorp; Olaf B Paulson; Marianne Juhler; Niels Vidiendal Olsen
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  Erythropoietin reverts cognitive impairment and alters the oxidative parameters and energetic metabolism in sepsis animal model.

Authors:  Clarissa M Comim; Omar J Cassol; Igor Abreu; Thais Moraz; Larissa S Constantino; Francieli Vuolo; Letícia S Galant; Natália de Rochi; Meline O Dos Santos Morais; Giselli Scaini; Tatiana Barichello; Emílio L Streck; João Quevedo; Felipe Dal-Pizzol
Journal:  J Neural Transm (Vienna)       Date:  2012-02-19       Impact factor: 3.575

Review 5.  Oxidative mechanisms of brain dysfunction during sepsis.

Authors:  Felipe Dal-Pizzol; Cristiane Ritter; Omar J Cassol; Gislaine T Rezin; Fabrícia Petronilho; Alexandra I Zugno; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2009-08-14       Impact factor: 3.996

Review 6.  Bench to bedside: A role for erythropoietin in sepsis.

Authors:  Andrew P Walden; J Duncan Young; Edward Sharples
Journal:  Crit Care       Date:  2010-08-06       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.